References
- Brown GD , DenningDW, GowNA, LevitzSM, NeteaMG, WhiteTC. Hidden killers: human fungal infections. Sci. Transl. Med.19 (4), 165 (2012).
- Park BJ , WannemuehlerKA, MarstonBJ, GovenderN, PappasPG, ChillerTM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS23 (4), 525–530 (2009).
- Sloan DJ , DedicoatMJ, LallooDG. Treatment of cryptococcal meningitis in resource-limited settings. Curr. Opin. Infect. Dis.22 (5), 455–463 (2009).
- Boulware DR , MeyaDB, MuzooraCet al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N. Engl. J. Med.370 (26), 2487–2498 (2014).
- Loyse A , ThangarajH, EasterbrookPet al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect. Dis.13 (7), 629–637 (2013).
- Day JN , ChauTT, WolbersMet al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med.368 (14), 1291–1302 (2013).
- Loyse A , DromerF, DayJ, LortholaryO, HarrisonTS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J. Antimicrob. Chemother.68 (11), 2435–2444 (2013).
- Jarvis JN , BicanicT, LoyseAet al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin. Infect. Dis.58 (5), 736–745 (2014).
- Thompson GR 3rd , RendonA, Dos SantosRRet al. Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin. Infect. Dis. pii: ciw305 (2016) ( Epub ahead of print).
- Butts A , DiDoneL, KoselnyKet al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell12 (2), 278–287 (2013).
- Brown JC , NelsonJ, VanderSluisBet al. Unraveling the biology of a fungal meningitis pathogen using chemical genetics. Cell159 (5), 1168–1187 (2014).
- Maligie MA , SelitrennikoffCP. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother.49 (7), 2851–2856 (2005).
- Rabjohns JL , ParkYD, DehdashtiJet al. A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans. J. Biomol. Screen.19 (2), 270–277 (2014).
- Hartland K , PuJ, PalmerMet al. High-throughput screen in Cryptococcus neoformans identifies a novel molecular scaffold that inhibits cell wall integrity pathway signaling. ACS Infect. Dis.2 (1), 93–102 (2016).
- Frail DE , BradyM, EscottKJet al. Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat. Rev. Drug Discov.14 (12), 833–841 (2015).
- Zhai B , WuC, WangL, SachsMS, LinX. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob. Agents Chemother.56 (7), 3758–3766 (2012).
- Rhein J , MorawskiBM, HullsiekKHet al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect. Dis.16 (7), 809–818 (2016)